ERBB2 and neoplasm: Tumors were classified in four molecular subtypes according to the tumor staining for ER/PR and HER2 status: 211 (51.9 %) were HER2 negative, luminal A or luminal B (ER and/or PR positive); 84 (20.6 %) were HER2 positive, luminal B (ER and/or PR positive); 53 (13.0 %) were HER2 enriched (ER and PR negative, HER2 positive); 59 (14.5 %) were triple negative (ER and PR negatives, HER2 negative).